|
1
|
Oldenburg J, Berney DM, Bokemeyer C,
Climent MA, Daugaard G, Gietema JA, De Giorgi U, Haugnes HS,
Huddart RA, Leão R, et al: Testicular seminoma and non-seminoma:
ESMO-EURACAN clinical practice guideline for diagnosis, treatment
and follow-up. Ann Oncol. 33:362–375. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gilligan T, Lin DW, Aggarwal R, Chism D,
Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock
SL, et al: Testicular cancer, version 2.2020, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
17:1529–1554. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boormans JL, Sylvester R, Anson-Cartwright
L, Glicksman RM, Hamilton RJ, Hahn E, Daugaard G, Lauritsen J,
Wagner T, Avuzzi B, et al: Prognostic factor risk groups for
clinical stage I seminoma: An individual patient data analysis by
the European association of urology testicular cancer guidelines
panel and guidelines office. Eur Urol Oncol. S2588-9311(23)00232-8.
2023.(Epub ahead of print). View Article : Google Scholar
|
|
4
|
von Amsberg G, Hamilton R and
Papachristofilou A: Clinical stage IIA-IIC seminoma: Radiation
therapy versus systemic chemotherapy versus retroperitoneal lymph
node dissection. Oncol Res Treat. 41:360–363. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giannatempo P, Greco T, Mariani L, Nicolai
N, Tana S, Farè E, Raggi D, Piva L, Catanzaro M, Biasoni D, et al:
Radiotherapy or chemotherapy for clinical stage IIA and IIB
seminoma: A systematic review and meta-analysis of patient
outcomes. Ann Oncol. 26:657–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naoun N, Bernard-Tessier A and Fizazi K:
Stage II seminoma: Why chemotherapy should remain a standard. Eur
Urol Open Sci. 49:69–70. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wood GE, Chamberlain F, Tran B, Conduit C,
Liow E, Nicol DL, Shamash J, Alifrangis C and Rajan P: Treatment
de-escalation for stage II seminoma. Nat Rev Urol. 20:502–512.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Travis LB, Beard C, Allan JM, Dahl AA,
Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan
R, et al: Testicular cancer survivorship: Research strategies and
recommendations. J Natl Cancer Inst. 102:1114–1130. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fung C, Dinh P Jr, Ardeshir-Rouhani-Fard
S, Schaffer K, Fossa SD and Travis LB: Toxicities associated with
cisplatin-based chemotherapy and radiotherapy in long-term
testicular cancer survivors. Adv Urol. 2018:86718322018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kou F, Gao S, Liu S, Wang X, Chen H, Zhu
X, Guo J, Zhang X, Feng A and Liu B: Preliminary clinical efficacy
of iodine-125 seed implantation for the treatment of advanced
malignant lung tumors. J Cancer Res Ther. 15:1567–1573. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Jiang Y, Ji Z, Jiang P, Xu F,
Zhang Y, Zhang P, Guo F, Li X, Sun H, et al: Dosimetry, efficacy,
and safety of three-dimensional printing noncoplanar
template-assisted and CT-guided 125I seed implantation
for recurrent retroperitoneal lymphatic metastasis after external
beam radiotherapy. Brachytherapy. 19:380–388. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen L, Ying X, Zhang D, Lai L, Wu F, Tu J
and Ji J: Iodine-125 brachytherapy can prolong progression-free
survival of patients with locoregional recurrence and/or residual
hepatocellular carcinoma after radiofrequency ablation. Cancer
Biother Radiopharm. 36:820–826. 2021.PubMed/NCBI
|
|
13
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
267:93–99. 2017. View Article : Google Scholar
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fosså SD, Dahl AA, Thorsen L, Hellesnes R,
Kiserud CE, Tandstad T, Brydøy M, Haugnes HS and Myklebust TÅ:
Mortality and second cancer incidence after treatment for
testicular cancer: Psychosocial health and lifestyle are modifiable
prognostic factors. J Clin Oncol. 40:2588–2599. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alsyouf M and Daneshmand S: Clinical stage
II seminoma: Management options. World J Urol. 40:343–348. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Honecker F, Aparicio J, Berney D, Beyer J,
Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G,
Dieckmann KP, et al: ESMO consensus conference on testicular germ
cell cancer: Diagnosis, treatment and follow-up. Ann Oncol.
29:1658–1686. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horwich A, Dearnaley DP, Sohaib A, Pennert
K and Huddart RA: Neoadjuvant carboplatin before radiotherapy in
stage IIA and IIB seminoma. Ann Oncol. 24:2104–2107. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Papachristofilou A, Bedke J, Hayoz S,
Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A,
Aebersold DM, Putora PM, et al: LBA30 single-dose carboplatin
followed by involved-node radiotherapy as curative treatment for
seminoma stage IIA/B: Efficacy results from the international
multicenter phase II trial SAKK 01/10. Ann Oncol. 32 (Suppl
5):S13052021. View Article : Google Scholar
|
|
20
|
Douglawi A, Calaway A, Tachibana I,
Panizzutti Barboza M, Speir R, Masterson T, Adra N, Foster R,
Einhorn L and Cary C: Long-term oncologic outcomes after primary
retroperitoneal lymph node dissection: Minimizing the need for
adjuvant chemotherapy. J Urol. 204:96–103. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heidenreich A, Paffenholz P, Hartmann F,
Seelemeyer F and Pfister D: Retroperitoneal lymph node dissection
in clinical stage IIA/B metastatic seminoma: Results of the cologne
trial of retroperitoneal lymphadenectomy in metastatic seminoma
(COTRIMS). Eur Urol Oncol. 7:122–127. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tachibana I, Alabd A, Piroozi A, Mahmoud
M, Kern S, Tong Y, Masterson TA, Adra N, Foster R, Hanna NH, et al:
Oncologic outcomes of primary retroperitoneal lymph node dissection
(RPLND) for stage II seminoma: Indiana University experience. J
Clin Oncol. 40 (16 Suppl):e170122022. View Article : Google Scholar
|
|
23
|
Lusch* A, Hiester A, Siemer RG, Paffenholz
P, Heidenreich A and Albers P: PD56-05 the primetest trial-interim
analysis of a phase II trial for primary retroperitoneal lymph node
dissection (RPLND) in stage II A/B seminoma patients without
adjuvant treatment. J Urol. 201 (Suppl 4):e10192019. View Article : Google Scholar
|
|
24
|
Daneshmand S, Cary C, Masterson TA,
Einhorn L, Boorjian SA, Kollmannsberger CK, Schuckman AK, So A,
Black PC, Bagrodia A, et al: SEMS trial: Result of a prospective,
multi-institutional phase II clinical trial of surgery in early
metastatic seminoma. J Clin Oncol. 39 (6 Suppl):S3752021.
View Article : Google Scholar
|
|
25
|
Huddart RA, Reid AH, Mayer E, Sohaib SA
and Nicol D: Clinical outcomes of minimally invasive
retroperitoneal lymph node dissection and single dose carboplatin
for clinical stage IIa seminoma. J Clin Oncol. 37 (7
Suppl):S5302019. View Article : Google Scholar
|
|
26
|
Rønde HS, Kronborg C, Høyer M, Hansen J,
Bak ME, Agergaard SN, Als AB, Agerbæk M, Lauritsen J, Meidahl
Petersen P, et al: Dose comparison of robustly optimized intensity
modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for
testicular seminoma. Acta Oncol. 62:1222–1229. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Savelyeva AV and Medvedev KE: Seminoma
subtypes differ in the organization and functional state of the
immune microenvironment. 3 Biotech. 13:1102023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen H, Shih J, Hollern DP, Wang L, Bowlby
R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, et al:
Integrated molecular characterization of testicular germ cell
tumors. Cell Rep. 23:3392–3406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pectasides D, Nikolaou M, Pectasides E,
Koumarianou A, Valavanis C and Economopoulos T: Complete response
after imatinib mesylate administration in a patient with
chemoresistant stage IV seminoma. Anticancer Res. 28:2317–2320.
2008.PubMed/NCBI
|
|
30
|
Cathomas R, Klingbiel D, Bernard BD, Lorch
A, Garcia del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C,
Haugnes HS, et al: FDG PET scan (PET) positive residual lesions
after chemotherapy (chemo) for metastatic seminoma: Results of an
international global germ cell cancer group (G3) registry. J Clin
Oncol. 35 (15 Suppl):S45212017. View Article : Google Scholar
|
|
31
|
Chen C, Wang W, Yu Z, Tian S, Li Y and
Wang Y: Combination of computed tomography-guided iodine-125
brachytherapy and bronchial arterial chemoembolization for locally
advanced stage III non-small cell lung cancer after failure of
concurrent chemoradiotherapy. Lung Cancer. 146:290–296. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chin J, Rumble RB, Kollmeier M, Heath E,
Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A and Loblaw DA:
Brachytherapy for patients with prostate cancer: American society
of clinical oncology/cancer care ontario joint guideline update. J
Clin Oncol. 35:1737–1743. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharma R, Sagoo NS, Haider AS, Sharma N,
Haider M, Sharma IK, Igbinigie M, Aya KL, Aoun SG and Vira S:
Iodine-125 radioactive seed brachytherapy as a treatment for spine
and bone metastases: A systematic review and meta-analysis. Surg
Oncol. 38:1016182021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu HT, Luo JP, Cao GS, Li Z, Jiang M, Guo
CY, Yuan H, Yao QJ, Geng X, Park JH, et al: Hepatocellular
Carcinoma With Portal Vein Tumor Thrombus Treated With
Transarterial Chemoembolization and Sorafenib vs
125iodine implantation. Front Oncol. 11:8069072021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tookman L, Rashid S, Matakidou A, Phillips
M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S, Harland S,
Sarwar N, et al: Carboplatin AUC 10 for IGCCCG good prognosis
metastatic seminoma. Acta Oncol. 52:987–993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shamash J, Syed R, Sarker SJ, Sarwar N,
Sharma A, Mutsvangwa K, Coetzee C, Wilson P and Rustin GJ: A phase
II study of carboplatin AUC-10 guided by positron emission
tomography-defined metabolic response in metastatic seminoma. Eur J
Cancer. 115:128–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
